HC Wainwright Estimates Insmed’s Q1 Earnings (NASDAQ:INSM)

Insmed Incorporated (NASDAQ:INSM) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Insmed in a report issued on Friday, February 21st. HC Wainwright analyst A. Fein forecasts that the biopharmaceutical company will post earnings of ($1.47) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $90.00 target price on the stock. The consensus estimate for Insmed’s current full-year earnings is ($4.56) per share. HC Wainwright also issued estimates for Insmed’s Q2 2025 earnings at ($1.42) EPS, Q3 2025 earnings at ($1.41) EPS and Q4 2025 earnings at ($1.22) EPS.

A number of other equities analysts also recently commented on the company. Wells Fargo & Company lifted their price objective on Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 19th. Truist Financial lifted their price objective on Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a research report on Friday. Stifel Nicolaus reduced their price objective on Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a research report on Friday. JPMorgan Chase & Co. lifted their price objective on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. Finally, Morgan Stanley lifted their price objective on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. One investment analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $91.00.

Insmed Stock Performance

Shares of Insmed stock opened at $81.06 on Monday. Insmed has a one year low of $21.92 and a one year high of $84.91. The company has a market cap of $14.50 billion, a price-to-earnings ratio of -14.50 and a beta of 1.11. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The business’s 50 day moving average price is $74.29 and its 200 day moving average price is $73.61.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The firm had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%.

Insider Activity

In other news, CEO William Lewis sold 2,978 shares of the company’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $63.36, for a total value of $188,686.08. Following the completion of the transaction, the chief executive officer now owns 392,589 shares in the company, valued at approximately $24,874,439.04. This represents a 0.75 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Martina M.D. Flammer sold 6,172 shares of the company’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $63.64, for a total transaction of $392,786.08. Following the completion of the transaction, the insider now owns 101,549 shares of the company’s stock, valued at approximately $6,462,578.36. The trade was a 5.73 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 532,207 shares of company stock worth $41,400,465. Corporate insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of INSM. Elequin Capital LP purchased a new stake in Insmed in the 4th quarter valued at $28,000. Steward Partners Investment Advisory LLC raised its position in Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 163 shares during the last quarter. V Square Quantitative Management LLC raised its position in Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 248 shares during the last quarter. Spire Wealth Management purchased a new stake in Insmed in the 4th quarter valued at $47,000. Finally, Smartleaf Asset Management LLC raised its position in Insmed by 98.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 411 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.